GlassScriptPhysician profile
Matthew S Cooper
NPI 1871755009
$1,637.34
in general payments reported to CMS, 2019-2025
21 companies · $78.85 in 2025
The $78.85 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $155 · 2021: $188 · 2022: $71.02 · 2023: $122 · 2024: $151 · 2025: $78.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $351.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $234.22 | 2019-2024 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $186.40 | 2019-2021 | |
| Glaxosmithkline, LLC. | $148.01 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $139.01 | 2019 | |
| Mannkind Corporation | $123.44 | 2019 | |
| Pfizer INC. | $112.12 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $101.69 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.64 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $81.17 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $53.31 | 2019-2020 | |
| Amarin Pharma, INC. | $51.84 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.00 | 2019 | |
| Genentech USA, INC. | $43.49 | 2019-2021 | |
| Abbvie INC. | $42.24 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Medtronic, INC. | $38.76 | 2023 | Minimed 780g |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.42 | 2022-2024 | Mounjaro, Zepbound |
| Ani Pharmaceuticals, INC. | $31.99 | 2024-2025 | Valsartan, Purified Cortrophin Gel |
| Sanofi Pasteur INC. | $28.21 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $15.25 | 2023 | Edarbi |
| Exact Sciences Corporation | $12.77 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.